Tejas Savant
Stock Analyst at Morgan Stanley
(2.19)
# 2,652
Out of 4,728 analysts
217
Total ratings
39.53%
Success rate
-4.35%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher | Maintains: Overweight | $670 → $647 | $555.08 | +16.56% | 13 | Jan 13, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $156 → $150 | $138.70 | +8.15% | 6 | Jan 13, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $84 → $82 | $70.18 | +16.84% | 8 | Jan 13, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $30 → $28 | $15.33 | +82.65% | 12 | Jan 13, 2025 | |
| STVN Stevanato Group | Assumes: Equal-Weight | $24 → $23 | $21.94 | +4.83% | 1 | Dec 3, 2024 | |
| GRAL GRAIL | Initiates: Equal-Weight | $16 | $18.12 | -11.71% | 1 | Nov 27, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $26 → $28 | $40.82 | -31.41% | 13 | Nov 18, 2024 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $32 → $21 | $13.56 | +54.92% | 2 | Nov 18, 2024 | |
| NTRA Natera | Maintains: Overweight | $132 → $176 | $164.98 | +6.68% | 12 | Nov 14, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $280 → $265 | $200.76 | +32.00% | 10 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $11 → $10 | $4.58 | +118.58% | 12 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.82 | +9.89% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $2.86 | +4.90% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $21.87 | +32.63% | 15 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $32.62 | +34.91% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.55 | +368.11% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $7.20 | -2.71% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $12.45 | +36.50% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $6.18 | +61.81% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $7.70 | +107.81% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.81 | +231.49% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.38 | +195.86% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $1.10 | +150.00% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $5.05 | -1.08% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.24 | +347.43% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $36.43 | +100.38% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $179.97 | +38.91% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.18 | +323.73% | 5 | May 12, 2022 |
Thermo Fisher
Jan 13, 2025
Maintains: Overweight
Price Target: $670 → $647
Current: $555.08
Upside: +16.56%
Illumina
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $156 → $150
Current: $138.70
Upside: +8.15%
Hologic
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $84 → $82
Current: $70.18
Upside: +16.84%
10x Genomics
Jan 13, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $15.33
Upside: +82.65%
Stevanato Group
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $21.94
Upside: +4.83%
GRAIL
Nov 27, 2024
Initiates: Equal-Weight
Price Target: $16
Current: $18.12
Upside: -11.71%
Veracyte
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $40.82
Upside: -31.41%
Myriad Genetics
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $13.56
Upside: +54.92%
Natera
Nov 14, 2024
Maintains: Overweight
Price Target: $132 → $176
Current: $164.98
Upside: +6.68%
IQVIA Holdings
Nov 4, 2024
Maintains: Overweight
Price Target: $280 → $265
Current: $200.76
Upside: +32.00%
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $11 → $10
Current: $4.58
Upside: +118.58%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.82
Upside: +9.89%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $2.86
Upside: +4.90%
Jul 29, 2024
Maintains: Overweight
Price Target: $28 → $29
Current: $21.87
Upside: +32.63%
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $32.62
Upside: +34.91%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.55
Upside: +368.11%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.20
Upside: -2.71%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $12.45
Upside: +36.50%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $6.18
Upside: +61.81%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $7.70
Upside: +107.81%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.81
Upside: +231.49%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.38
Upside: +195.86%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $1.10
Upside: +150.00%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.05
Upside: -1.08%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.24
Upside: +347.43%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $36.43
Upside: +100.38%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $179.97
Upside: +38.91%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.18
Upside: +323.73%